Data gathered: February 1
AI Stock Analysis - Lantheus (LNTH)
Analysis generated November 15, 2024. Powered by Chat GPT.
Lantheus Holdings, Inc. is a prominent player in the healthcare sector, primarily specializing in diagnostic imaging agents and products. The company provides medical imaging solutions that help healthcare professionals diagnose and treat diseases more effectively. Lantheus’ portfolio includes nuclear imaging, ultrasound contrast agents, and other imaging products. Given its critical role in the healthcare diagnostics market, Lantheus is well-positioned to benefit from the ongoing advancements in medical technologies.
Stock Alerts - Lantheus (LNTH)
 |
Lantheus | January 28 News Alert: Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader |
|
Lantheus | January 28 Price is down by -5.2% in the last 24h. |
|
Lantheus | January 18 Insider Alert: Thrall James H is selling shares |
|
Lantheus | January 13 News Alert: Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market |
Alternative Data for Lantheus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 81 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 20,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 30 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,466 | Sign up | Sign up | Sign up |
| Twitter Followers | 362 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $63,000 | Sign up | Sign up | Sign up |
| Business Outlook | 82 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,137 | Sign up | Sign up | Sign up |
About Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
| Price | $92.51 |
| Target Price | Sign up |
| Volume | 790,680 |
| Market Cap | $6.45B |
| Year Range | $76.22 - $123.62 |
| Dividend Yield | 0% |
| PE Ratio | 15.41 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board MemberJanuary 30 - GlobeNewswire |
|
Why Lantheus Holdings Stock Got Thrashed on TuesdayJanuary 29 - Yahoo Entertainment |
|
 |
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical PortfolioJanuary 28 - Biztoc.com |
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical LeaderJanuary 28 - GlobeNewswire |
|
 |
Avior Wealth Management LLC Has $414,000 Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)January 27 - ETF Daily News |
|
UMB Bank n.a. Acquires 134 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)January 25 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 379M | 233M | 242M | 131M | 189M | 1.700 |
| Q2 '24 | 394M | 241M | 256M | 62M | 92M | 1.800 |
| Q1 '24 | 365M | 232M | 242M | 131M | 186M | 1.690 |
| Q4 '23 | 349M | 237M | 230M | 103M | 181M | 1.750 |
| Q3 '23 | 315M | 196M | 200M | 132M | 168M | 1.470 |
Insider Transactions View All
| Thrall James H filed to sell 33,207 shares at $94.8. January 17 '25 |
| Marshall Robert J. Jr. filed to sell 102,963 shares at $81.2. November 19 '24 |
| Blanchfield Paul filed to sell 97,092 shares at $79.7. November 18 '24 |
| Heino Mary Anne filed to sell 447,036 shares at $86.9. November 12 '24 |
| Heino Mary Anne filed to sell 443,436 shares at $89.6. November 12 '24 |
Similar companies
Read more about Lantheus (LNTH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Lantheus?
The Market Cap of Lantheus is $6.45B.
What is Lantheus' PE Ratio?
As of today, Lantheus' PE (Price to Earnings) ratio is 15.41.
What is the current stock price of Lantheus?
Currently, the price of one share of Lantheus stock is $92.51.
How can I analyze the LNTH stock price chart for investment decisions?
The LNTH stock price chart above provides a comprehensive visual representation of Lantheus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lantheus shares. Our platform offers an up-to-date LNTH stock price chart, along with technical data analysis and alternative data insights.
Does LNTH offer dividends to its shareholders?
As of our latest update, Lantheus (LNTH) does not offer dividends to its shareholders. Investors interested in Lantheus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lantheus?
Some of the similar stocks of Lantheus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.